Financial Data and Key Metrics Changes - Total company revenue increased by 5.7% to $1.164 billion in 2025, or 5.2% growth on a constant currency basis compared to 2024 [5][15] - Adjusted EBITDA rose by 8.2% to $593.8 million, with adjusted EBITDA margins expanding to 51%, an increase of 118 basis points [5][15] - Adjusted free cash flow exceeded $200 million in 2025 [5] - For Q4 2025, total revenues increased by 4.6% to $303 million, or 2.5% on a constant currency basis [11] Business Line Data and Key Metrics Changes - Sterigenics revenue improved by 10.6% to $198 million, driven by favorable pricing and volume [12] - Nordion's revenue decreased by 12.3% to $50 million due to unfavorable volume and mix from Cobalt-60 harvest timing [13] - Nelson Labs revenue increased by 2.3% to $55 million, with favorable pricing partially offset by lower expert advisory services revenue [14] Market Data and Key Metrics Changes - Customer satisfaction exceeded 80%, indicating strong service delivery [6] - Revenue from XBU customers expanded by 9% year-over-year [6] Company Strategy and Development Direction - The company is focused on executing its 2025-2027 long-range plan, with expectations for continued growth and operational excellence [8] - The strategic decision to enhance the X-ray facility is aimed at expanding service offerings across all modalities [44][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive long-term growth and shareholder value, emphasizing strong cash flow and customer relationships [21] - The guidance for 2026 anticipates total revenue growth to a range of $1.233 billion-$1.251 billion, representing 5%-6.5% constant currency growth [9][18] Other Important Information - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in annual interest savings of $13 million [7] - A management transition was announced, with Erika Ostrowski promoted to Senior Vice President and General Counsel [10] Q&A Session Summary Question: Guidance and EBITDA margins - The midpoint of the guidance implies about 20 basis points of expansion, driven by normal operating leverage [23][24] Question: Sterigenics client insourcing - Management noted that while one client is transitioning back to outsourcing, significant shifts are not expected at this time due to regulatory compliance timelines [25][26] Question: 2026 outlook for Sterigenics - Expected mid to high single-digit constant currency revenue growth for Sterigenics in 2026, with a soft start anticipated in Q1 [32][42] Question: Nelson Labs margins - Nelson Labs is expected to maintain margins in the low to mid-30s, with Q1 being the lightest quarter [34][35] Question: Nordion segment headwinds - Revenue challenges were attributed to Cobalt-60 harvest timing rather than demand issues [84][85] Question: Competitive positioning in Sterigenics - Management indicated that while NESHAP compliance discussions are ongoing, the urgency has decreased due to extended deadlines [68][69] Question: Impact of tariffs and onshoring - The company has not seen significant impacts from tariffs or onshoring trends, maintaining a strong market position [87][88]

Financial Data and Key Metrics Changes - Total company revenue increased by 5.7% to $1.164 billion in 2025, or 5.2% growth on a constant currency basis compared to 2024 [5][15] - Adjusted EBITDA rose by 8.2% to $593.8 million, or 7.8% on a constant currency basis, with margins expanding to 51%, an increase of 118 basis points [5][15] - Adjusted EPS for the year was $0.86, an increase of $0.16 versus 2024, driven by operational growth and a lower tax rate [16] Business Line Data and Key Metrics Changes - Sterigenics revenue improved by 10.6% to $198 million, or 8% on a constant currency basis, driven by favorable pricing and volume [12] - Nordion's revenue decreased by 12.3% to $50 million due to unfavorable volume and mix from Cobalt-60 harvest timing [13] - Nelson Labs revenue increased by 2.3% to $55 million, with favorable pricing and core lab testing growth partially offset by lower advisory services revenue [14] Market Data and Key Metrics Changes - Customer satisfaction exceeded 80%, indicating strong service delivery [6] - Revenue from XBU customers expanded by 9% year-over-year, reflecting successful cross-selling initiatives [6][50] Company Strategy and Development Direction - The company aims to execute its 2025-2027 long-range plan, focusing on operational excellence, disciplined capital deployment, and enhancing free cash flow [8][21] - The construction of a new X-ray facility is planned to open in 2026, which is part of a strategic investment to expand service offerings [6][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive long-term growth and shareholder value, emphasizing strong cash flow generation and customer relationships [21][105] - The company expects total revenue for 2026 to be in the range of $1.233 billion to $1.251 billion, representing 5%-6.5% constant currency growth [9][18] Other Important Information - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in annual interest savings of $13 million [7] - The company has approximately $940 million of available liquidity as of December 31, 2025 [16] Q&A Session Summary Question: Guidance and EBITDA margins - Management indicated that the expected EBITDA margin expansion is primarily due to normal operating leverage without any unusual dynamics [23][24] Question: Sterigenics client insourcing - Management noted that while one client is transitioning back to outsourcing, significant shifts in the market are not yet observed due to extended compliance periods [25][26] Question: 2026 outlook for Sterigenics - Management expects mid to high single-digit constant currency revenue growth for Sterigenics in 2026, with a soft start anticipated in Q1 [18][32] Question: Nelson Labs margins - Management expects Nelson Labs to maintain margins in the low to mid 30% range, with Q1 typically being the softest quarter [34][35] Question: Nordion segment headwinds - Management clarified that Nordion's challenges were due to Cobalt-60 harvest timing rather than demand issues [84][85] Question: Competitive positioning in Sterigenics - Management believes Sterigenics is well-positioned despite the extended compliance period, with strong customer satisfaction scores [68][69] Question: Impact of onshoring - Management has not seen significant movement towards onshoring but is prepared for potential shifts in the market [87] Question: Volume and mix visibility - Management indicated that volume and mix are key factors that could drive performance towards the higher end of guidance [91][92]

Financial Data and Key Metrics Changes - Total company revenue increased by 5.7% to $1.164 billion in 2025, or 5.2% growth on a constant currency basis compared to 2024 [4][13] - Adjusted EBITDA rose by 8.2% to $593.8 million, or 7.8% on a constant currency basis, with adjusted EBITDA margins expanding to 51%, an increase of 118 basis points [4][13] - Adjusted EPS for the year was $0.86, an increase of $0.16 versus 2024, driven by operational growth and a lower tax rate [14] Business Line Data and Key Metrics Changes - Sterigenics revenue improved by 10.6% to $198 million, or 8% on a constant currency basis, driven by favorable pricing and volume [11] - Nordion's revenue decreased by 12.3% to $50 million due to unfavorable volume and mix from Cobalt-60 harvest schedules [12] - Nelson Labs revenue increased by 2.3% to $55 million, with segment income rising by 1.9% to $18 million [12][13] Market Data and Key Metrics Changes - Customer satisfaction exceeded 80%, indicating strong service delivery [5] - Revenue from XBU customers expanded by 9% year-over-year, reflecting successful commercial initiatives [5][48] Company Strategy and Development Direction - The company is focused on executing its 2025-2027 long-range plan, emphasizing operational excellence and disciplined capital deployment [7][20] - The construction of a new X-ray facility is planned to open in 2026, aimed at enhancing service offerings across sterilization modalities [5][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive long-term growth and shareholder value, citing a strong balance sheet and cash flow generation [20] - The company expects total revenue for 2026 to increase to a range of $1.233 billion-$1.251 billion, representing 5%-6.5% constant currency growth [8][17] Other Important Information - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in annual interest savings of $13 million [6] - Adjusted free cash flow was $210 million in 2025, aligning with the company's goal of achieving $500 million-$600 million in cumulative free cash flow by 2027 [14][15] Q&A Session Summary Question: Guidance and EBITDA margins - The midpoint of the guidance implies about 20 basis points of expansion, driven by normal operating leverage [22][23] Question: Sterigenics client insourcing - There is no significant shift in insourcing; one customer will start bringing volume in late 2025 [24][25] Question: 2026 outlook for Sterigenics - Expecting mid to high single digits constant currency revenue growth for Sterigenics in 2026 [30][31] Question: Nelson Labs margins - Nelson Labs is expected to maintain low to mid 30% margins in 2026, with Q1 being the lightest quarter [32][33] Question: X-ray facility opening - The X-ray facility is expected to open in the second half of 2026, with a ramp-up period for customer qualifications [40][42] Question: Competitive positioning in Sterigenics - Sterigenics is well-positioned despite the NESHAP extension, with strong customer satisfaction and a global service model [66][67] Question: Nordion segment headwinds - The decrease in Nordion's revenue was driven by Cobalt-60 harvest timing, not demand issues [81][83] Question: Onshoring impact - No significant movement towards onshoring has been observed, but the company is well-positioned if it occurs [85][86] Question: Guidance visibility - Volume and mix are the key factors that could drive results towards the higher end of the guidance range [89][90]

Summary of Sotera Health Company FY Conference Call Company Overview - **Company Name**: Sotera Health Company (NasdaqGS:SHC) - **Mission**: Safeguarding global health through its three business units: Sterigenics, Nordion, and Nelson Labs [2][3] - **Global Presence**: Over 5,000 customers in 50 countries, 3,100 employees, and 62 facilities across 13 countries [3] - **Customer Base**: Engages with 40 of the top 50 medical device companies and 9 of the top 10 pharmaceutical companies [3] Business Segments Sterigenics - **Largest Business Unit**: Represents about two-thirds of the company's revenue [4] - **EBITDA Margins**: Approximately 50% [4] - **Sterilization Methods**: 39% ethylene oxide, 49% gamma, and 12% eBeam [5] - **Service Model**: Operates as a service business, where customers drop off products for sterilization [5] Nordion - **Product Business**: World's largest provider of Cobalt-60, critical for sterilization [6] - **EBITDA Margins**: Approximately 60% [7] - **Cobalt Sourcing**: Obtains Cobalt-60 from reactors in multiple countries including China, Canada, and Russia [6] Nelson Labs - **Testing Services**: Leader in microbiological and analytical chemistry testing with about 3,000 customers [7] - **Revenue Composition**: 48% routine testing, 37% validation, and 15% advisory services [8] Financial Performance - **Revenue Growth**: Surpassed $1.16 billion in revenue, with a minimum growth of over 5% [10] - **CAGR**: 7% growth in top line and adjusted EBITDA since going public in 2020 [11] - **Free Cash Flow**: Targeting $500 million to $600 million in cumulative free cash flow from 2025 to 2027 [20] - **Leverage Ratio**: Aiming to reduce net leverage from 3.3 times to a target of 2-3 times [12] Strategic Priorities 1. **Customer Service Excellence**: Focus on providing end-to-end solutions [13] 2. **Growth Market Segmentation**: Targeting high-growth segments within med tech and pharma [14] 3. **Operational Excellence**: Enhancing free cash flow through disciplined capital deployment [15] 4. **Long-term Value Creation**: Aiming for consistent top-line growth of 5%-7% annually [17] Market Outlook - **Growth Projections**: Sterigenics expected to grow mid-single to high-single digits, Nelson Labs mid-single digits, and Nordion low-single to mid-single digits [18] - **Pricing Strategy**: Anticipating a price increase of 3%-4% across the company [30] Regulatory Environment - **NESHAP Standards**: New regulations for ethylene oxide have been extended to April 2028, impacting smaller competitors [33] - **Litigation Updates**: Favorable rulings in Georgia regarding ethylene oxide litigation, with ongoing cases in California [52][54] Investment Rationale - **Market Position**: Leader in a growing $18 billion addressable market with strong margins and cash flow [24] - **Regulatory Expertise**: Established expertise in navigating highly regulated markets [24] - **Growth Potential**: Continued investment in capacity and operational improvements expected to drive future growth [25] Conclusion - **Company Confidence**: Strong execution and commitment to delivering growth and cash flow, positioning Sotera Health as a compelling investment opportunity for the future [55]

Summary of Soterra Health Conference Call Company Overview - **Company Name**: Soterra Health - **Ticker Symbol**: SHE - **Industry**: Healthcare, specifically focused on pharma services and sterilization Key Points and Arguments Business Performance and Outlook - Soterra Health expressed a positive outlook for 2025, reaffirming guidance and reporting good execution and customer care [5][6] - The company has experienced consistent growth since 2005, despite challenges posed by the pandemic [8][9] - Supply chain dynamics and labor challenges were highlighted as significant issues during and post-COVID, but the company has stabilized its turnover and service rates [10][11] Business Segments - **Nordion Business**: Consistent performer, though subject to quarterly lumpiness due to external factors like utility maintenance schedules [14][15] - **Nelson Labs**: Experienced volatility due to COVID and labor dynamics but is now stabilizing with improved service rates and quality [17][18] - **Sterigenics**: Initially saw flat to down volumes post-COVID but is normalizing with positive trends in bioprocessing and hospital supplies [19][20][21] Supply Chain and Tariff Impact - No significant impact from tariffs was reported, although there is interest from offshore customers wanting to increase volumes in the U.S. [22][23] - The company has not seen clients needing to mitigate tariff impacts through price negotiations [24][28] Competitive Positioning - Soterra Health and its competitor Steris hold approximately 50% to 66% of the market share collectively, with smaller players struggling to comply with new regulations [46][47] - The tightening of NESHAP regulations is expected to challenge smaller players, potentially leading to market share shifts towards Soterra Health [41][42][44] Capital Allocation and Growth Strategy - The company prioritizes disciplined capital allocation, focusing on organic growth and strategic acquisitions [69][70] - Plans to invest in new facilities and enhancements, with a commitment to maintaining a CapEx of around $110 million and generating over $500 million in free cash flow by 2027 [75] Regulatory Environment - The tightening regulatory environment is seen as a net positive for Soterra Health, as it may lead to increased demand for compliance services [41][44] - The company is well-positioned to meet regulatory requirements, which could create opportunities for growth [44][45] Customer Relationships and Synergies - There is a significant overlap between the customer bases of Sterigenics and Nelson Labs, with about 70% customer overlap and 40% of Nelson Labs' business related to sterility assurance [64][65] - The company aims to improve connectivity and customer satisfaction through better integration of services [66] Financial Performance - The company anticipates margin expansion primarily driven by Nelson Labs in 2025, with stable margins expected in Sterigenics and Nordion [74][75] Additional Important Insights - The company has been proactive in addressing labor and service quality issues, which are critical for maintaining customer satisfaction [61][62] - Soterra Health is cautious about acquiring smaller facilities due to compliance costs and challenges, preferring to focus on its existing network [54][55] This summary encapsulates the key insights from the Soterra Health conference call, highlighting the company's strategic direction, market positioning, and financial outlook.

Financial Data and Key Metrics Changes - Total company revenues increased by 2.6% to $255 million, or 4.4% on a constant currency basis compared to Q1 2024 [5][13] - Adjusted EBITDA increased by 8.8% to $122 million, equating to an 11.2% growth rate on a constant currency basis [5][15] - Adjusted EPS improved to $0.14 per share, a $0.01 increase versus Q1 2024 [5][16] - Net loss on a GAAP basis was $13 million, or $0.05 per diluted share, compared to a net income of $6 million, or $0.02 per diluted share in Q1 2024 [15][16] Business Line Data and Key Metrics Changes - **Sterigenics**: Revenue grew by 1.9% to $170 million, or 3.9% on a constant currency basis, with segment income increasing by 2.5% to $88 million [17][18] - **Nordion**: Revenue surged by 36% to $33 million, or 40.6% on a constant currency basis, with segment income increasing approximately 62% to $17.4 million [18][19] - **Nelson Labs**: Revenue declined by 9.3% to $52 million, but segment income increased by 7% to $60 million, driven by favorable volume and mix from improved core lab testing [20][21] Market Data and Key Metrics Changes - The company operates in a $4.5 billion sterilization service addressable market, with positive trends driven by an aging population, healthcare spending, product innovation, and stringent regulatory requirements [6] - The foreign currency presented a headwind of 180 basis points for the quarter, most pronounced in the Canadian-based Nordion business [13] Company Strategy and Development Direction - The company aims for revenue growth in the range of 4% to 6% and adjusted EBITDA growth of 4.5% to 6.5% on a constant currency basis for 2025 [9][22] - The strategic focus includes excellence in customer service, winning in growth markets, driving operational excellence, and disciplined capital deployment [28] - The company plans to prioritize organic growth and deleveraging, along with opportunistic M&A [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the recovery of Sterigenics and noted that volumes are expected to improve throughout the year [34][46] - The company does not anticipate current tariff policies to have a material impact on its business, with 85% of total revenue being service revenue [9][23] - Management reaffirmed the outlook for 2025, indicating that the foreign exchange headwind has improved compared to previous estimates [22] Other Important Information - The company has $715 million of available liquidity, including over $300 million of unrestricted cash [21] - Capital expenditures for Q1 2025 totaled $20 million, with expectations for full-year capital expenditures in the range of $190 million to $210 million [21][26] Q&A Session Summary Question: Impact of tariffs on the business - Management expressed confidence that current regulations will not have a material impact on the company, particularly regarding cobalt shipments from Canada to the U.S. [31][32] Question: Volume recovery in Sterigenics and Nelson - Management noted optimism regarding volume improvements in both Sterigenics and Nelson Labs, supported by strong customer survey results [34][35] Question: Nelson Labs margin trends - Management highlighted that new regulations and product spend are driving improvements in margins, with expectations for continued growth throughout the year [40][41] Question: Legal strategy and ongoing cases - Management stated confidence in their legal strategy and ability to defend against claims, emphasizing the importance of scientific evidence [50][52] Question: Cross-selling initiatives between Nelson and Sterigenics - Management confirmed ongoing incentives for cross-selling and noted positive customer responses to integrated services [53][55] Question: Pricing levels and customer pushback - Management indicated that pricing for Sterigenics remains consistent with long-term targets, with ongoing discussions with customers about value delivery [75][78]